Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital System

Submitted by Anonymous on

The race-adjusted estimated glomerular filtration rate reduced Black patients’ access to kidney transplants. NYC Health+Hospitals is studying the effect of a race-neutral algorithm PerspectiveEfforts toward Equity Share on Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action...

An autosomal recessive nonsense variant in the EGFR gene induces perinatal lethality in “Blonde d'Aquitaine” calves

Submitted by Anonymous on

AbstractBackground Six cases of perinatal lethality associated with phenotypes consistent across cases, short and brush-haired appearance, alopecia and erythematous areas on the limbs and facial protuberances, excess skin all-over the body, have recently occurred in the "Blonde d'Aquitaine" cattle breed...

EGFR amplification and rapid early progression in glioblastoma: implications for timing and risk stratification

Submitted by Anonymous on

This is a preview of subscription content, log in via an institution to check access. Access this article Log in via an institution Subscribe and save Springer+ from €39.99 /Month Starting from 10 chapters or articles per month Access and...

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Submitted by Anonymous on

Original Article Share on Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCAuthors: Pasi A. Jänne, M.D., Ph.D., David Planchard, M.D., Ph.D., Kunihiko Kobayashi, M.D., Ph.D., James Chih-Hsin Yang, M.D., Ph.D., Ying Liu, M.D., Natalia Valdiviezo, M.D., Tae Min Kim,...

The Keller/eGFR ratio, frailty, and measured GFR: towards a new diagnostic framework for CKD in the elderly

Submitted by Anonymous on

This is a preview of subscription content, log in via an institution to check access. Access this article Log in via an institution Subscribe and save Springer+ from €39.99 /Month Starting from 10 chapters or articles per month Access and...

Cost-Effectiveness of Osimertinib Evaluated for EGFR-Mutated NSCLC Patients in US Healthcare System

Submitted by Anonymous on

Cost-Effectiveness of Osimertinib Evaluated for EGFR-Mutated NSCLC Patients in US Healthcare System A recent analysis has evaluated the cost-effectiveness of osimertinib, a targeted therapy for patients with resected epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), within the...

An updated cost-effectiveness analysis of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer: the perspective of the United States

Submitted by Anonymous on

AbstractBackground The ADAURA trial reported a significant overall survival benefit of the use of adjuvant treatment with osimertinib following complete resection of stage IB‒IIIA non-small cell lung cancer (NSCLC) with epidermal gerowth factor receptor (EGFR) mutation. Herein, we aimed to...

Subscribe to Newsfeed